nodes	percent_of_prediction	percent_of_DWPC	metapath
Dihydroergotamine—ABCB1—Topotecan—cervical cancer	0.504	0.625	CbGbCtD
Dihydroergotamine—CYP3A4—Topotecan—cervical cancer	0.302	0.375	CbGbCtD
Dihydroergotamine—Pleuritic pain—Topotecan—cervical cancer	0.0335	0.259	CcSEcCtD
Dihydroergotamine—Rigors—Topotecan—cervical cancer	0.00824	0.0638	CcSEcCtD
Dihydroergotamine—Ear pain—Topotecan—cervical cancer	0.00572	0.0443	CcSEcCtD
Dihydroergotamine—Cramp muscle—Topotecan—cervical cancer	0.0044	0.034	CcSEcCtD
Dihydroergotamine—Epistaxis—Topotecan—cervical cancer	0.00355	0.0275	CcSEcCtD
Dihydroergotamine—Rhinitis—Topotecan—cervical cancer	0.00339	0.0262	CcSEcCtD
Dihydroergotamine—Hypoaesthesia—Topotecan—cervical cancer	0.00336	0.026	CcSEcCtD
Dihydroergotamine—Pharyngitis—Topotecan—cervical cancer	0.00335	0.026	CcSEcCtD
Dihydroergotamine—Chills—Topotecan—cervical cancer	0.00303	0.0235	CcSEcCtD
Dihydroergotamine—Muscle spasms—Topotecan—cervical cancer	0.00283	0.0219	CcSEcCtD
Dihydroergotamine—Ill-defined disorder—Topotecan—cervical cancer	0.00273	0.0211	CcSEcCtD
Dihydroergotamine—Malaise—Topotecan—cervical cancer	0.00265	0.0205	CcSEcCtD
Dihydroergotamine—Myalgia—Topotecan—cervical cancer	0.0025	0.0194	CcSEcCtD
Dihydroergotamine—Arthralgia—Topotecan—cervical cancer	0.0025	0.0194	CcSEcCtD
Dihydroergotamine—Discomfort—Topotecan—cervical cancer	0.00247	0.0191	CcSEcCtD
Dihydroergotamine—Hyperhidrosis—Topotecan—cervical cancer	0.00232	0.018	CcSEcCtD
Dihydroergotamine—HTR2B—uterine cervix—cervical cancer	0.00231	0.0606	CbGeAlD
Dihydroergotamine—Anorexia—Topotecan—cervical cancer	0.00229	0.0177	CcSEcCtD
Dihydroergotamine—HTR2B—decidua—cervical cancer	0.0022	0.0577	CbGeAlD
Dihydroergotamine—Musculoskeletal discomfort—Topotecan—cervical cancer	0.00219	0.0169	CcSEcCtD
Dihydroergotamine—Paraesthesia—Topotecan—cervical cancer	0.00215	0.0167	CcSEcCtD
Dihydroergotamine—Dyspnoea—Topotecan—cervical cancer	0.00214	0.0166	CcSEcCtD
Dihydroergotamine—Dyspepsia—Topotecan—cervical cancer	0.00211	0.0164	CcSEcCtD
Dihydroergotamine—HTR2B—endometrium—cervical cancer	0.00209	0.0548	CbGeAlD
Dihydroergotamine—Decreased appetite—Topotecan—cervical cancer	0.00209	0.0161	CcSEcCtD
Dihydroergotamine—Fatigue—Topotecan—cervical cancer	0.00207	0.016	CcSEcCtD
Dihydroergotamine—Pain—Topotecan—cervical cancer	0.00205	0.0159	CcSEcCtD
Dihydroergotamine—Feeling abnormal—Topotecan—cervical cancer	0.00198	0.0153	CcSEcCtD
Dihydroergotamine—Gastrointestinal pain—Topotecan—cervical cancer	0.00196	0.0152	CcSEcCtD
Dihydroergotamine—HTR1A—renal system—cervical cancer	0.00194	0.0508	CbGeAlD
Dihydroergotamine—HTR2B—uterus—cervical cancer	0.00193	0.0505	CbGeAlD
Dihydroergotamine—HTR1B—female reproductive system—cervical cancer	0.00192	0.0504	CbGeAlD
Dihydroergotamine—Urticaria—Topotecan—cervical cancer	0.00191	0.0148	CcSEcCtD
Dihydroergotamine—Body temperature increased—Topotecan—cervical cancer	0.0019	0.0147	CcSEcCtD
Dihydroergotamine—Abdominal pain—Topotecan—cervical cancer	0.0019	0.0147	CcSEcCtD
Dihydroergotamine—HTR1D—female reproductive system—cervical cancer	0.00186	0.0488	CbGeAlD
Dihydroergotamine—Hypersensitivity—Topotecan—cervical cancer	0.00177	0.0137	CcSEcCtD
Dihydroergotamine—HTR6—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00175	0.0662	CbGpPWpGaD
Dihydroergotamine—HTR1D—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00174	0.0657	CbGpPWpGaD
Dihydroergotamine—HTR2B—female reproductive system—cervical cancer	0.00173	0.0454	CbGeAlD
Dihydroergotamine—Asthenia—Topotecan—cervical cancer	0.00172	0.0133	CcSEcCtD
Dihydroergotamine—HTR1B—Amine ligand-binding receptors—TAAR6—cervical cancer	0.0017	0.0644	CbGpPWpGaD
Dihydroergotamine—Pruritus—Topotecan—cervical cancer	0.0017	0.0131	CcSEcCtD
Dihydroergotamine—Diarrhoea—Topotecan—cervical cancer	0.00164	0.0127	CcSEcCtD
Dihydroergotamine—HTR2B—Amine ligand-binding receptors—TAAR6—cervical cancer	0.0016	0.0605	CbGpPWpGaD
Dihydroergotamine—Dizziness—Topotecan—cervical cancer	0.00159	0.0123	CcSEcCtD
Dihydroergotamine—HTR2B—vagina—cervical cancer	0.00157	0.0411	CbGeAlD
Dihydroergotamine—Vomiting—Topotecan—cervical cancer	0.00153	0.0118	CcSEcCtD
Dihydroergotamine—Rash—Topotecan—cervical cancer	0.00151	0.0117	CcSEcCtD
Dihydroergotamine—Dermatitis—Topotecan—cervical cancer	0.00151	0.0117	CcSEcCtD
Dihydroergotamine—Headache—Topotecan—cervical cancer	0.0015	0.0116	CcSEcCtD
Dihydroergotamine—ADRA2A—Platelet Aggregation (Plug Formation)—GP5—cervical cancer	0.00146	0.0552	CbGpPWpGaD
Dihydroergotamine—ADRA2A—uterine cervix—cervical cancer	0.00145	0.0381	CbGeAlD
Dihydroergotamine—Nausea—Topotecan—cervical cancer	0.00143	0.011	CcSEcCtD
Dihydroergotamine—ADRA2A—decidua—cervical cancer	0.00138	0.0363	CbGeAlD
Dihydroergotamine—ADRA2A—endometrium—cervical cancer	0.00131	0.0344	CbGeAlD
Dihydroergotamine—HTR1A—Amine ligand-binding receptors—TAAR6—cervical cancer	0.0013	0.049	CbGpPWpGaD
Dihydroergotamine—ADRA2A—mammalian vulva—cervical cancer	0.00127	0.0333	CbGeAlD
Dihydroergotamine—ADRA2A—uterus—cervical cancer	0.00121	0.0317	CbGeAlD
Dihydroergotamine—ADRA2A—female reproductive system—cervical cancer	0.00109	0.0285	CbGeAlD
Dihydroergotamine—CYP3A4—renal system—cervical cancer	0.00107	0.028	CbGeAlD
Dihydroergotamine—ADRA2A—Amine ligand-binding receptors—TAAR6—cervical cancer	0.00102	0.0385	CbGpPWpGaD
Dihydroergotamine—HTR2B—lymph node—cervical cancer	0.00101	0.0266	CbGeAlD
Dihydroergotamine—ADRA2A—female gonad—cervical cancer	0.00099	0.0259	CbGeAlD
Dihydroergotamine—ADRA2A—vagina—cervical cancer	0.000984	0.0258	CbGeAlD
Dihydroergotamine—CYP3A4—female reproductive system—cervical cancer	0.000856	0.0224	CbGeAlD
Dihydroergotamine—ABCB1—epithelium—cervical cancer	0.000816	0.0214	CbGeAlD
Dihydroergotamine—ABCB1—uterine cervix—cervical cancer	0.000809	0.0212	CbGeAlD
Dihydroergotamine—ABCB1—decidua—cervical cancer	0.000771	0.0202	CbGeAlD
Dihydroergotamine—ABCB1—renal system—cervical cancer	0.000757	0.0198	CbGeAlD
Dihydroergotamine—ABCB1—endometrium—cervical cancer	0.000732	0.0192	CbGeAlD
Dihydroergotamine—HTR6—G alpha (s) signalling events—TAAR6—cervical cancer	0.000722	0.0273	CbGpPWpGaD
Dihydroergotamine—ABCB1—mammalian vulva—cervical cancer	0.000708	0.0186	CbGeAlD
Dihydroergotamine—ABCB1—uterus—cervical cancer	0.000674	0.0177	CbGeAlD
Dihydroergotamine—ADRA2A—lymph node—cervical cancer	0.000636	0.0167	CbGeAlD
Dihydroergotamine—ABCB1—female reproductive system—cervical cancer	0.000606	0.0159	CbGeAlD
Dihydroergotamine—ABCB1—female gonad—cervical cancer	0.000552	0.0145	CbGeAlD
Dihydroergotamine—ABCB1—vagina—cervical cancer	0.000548	0.0144	CbGeAlD
Dihydroergotamine—ABCB1—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000513	0.0194	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—GP6—cervical cancer	0.0004	0.0151	CbGpPWpGaD
Dihydroergotamine—ABCB1—HIF-1-alpha transcription factor network—CA9—cervical cancer	0.000355	0.0134	CbGpPWpGaD
Dihydroergotamine—ABCB1—lymph node—cervical cancer	0.000355	0.00929	CbGeAlD
Dihydroergotamine—ADRA2A—Platelet activation, signaling and aggregation—GP5—cervical cancer	0.000349	0.0132	CbGpPWpGaD
Dihydroergotamine—HTR6—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000344	0.013	CbGpPWpGaD
Dihydroergotamine—HTR1D—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000342	0.0129	CbGpPWpGaD
Dihydroergotamine—HTR1B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000335	0.0127	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—RARB—cervical cancer	0.000316	0.012	CbGpPWpGaD
Dihydroergotamine—HTR2B—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000314	0.0119	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Tryptophan metabolism—UBE3A—cervical cancer	0.000304	0.0115	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—TAAR6—cervical cancer	0.000262	0.00992	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—TAAR6—cervical cancer	0.00026	0.00985	CbGpPWpGaD
Dihydroergotamine—HTR1A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.000255	0.00965	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—TAAR6—cervical cancer	0.000255	0.00964	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—TAAR6—cervical cancer	0.000239	0.00906	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—GP6—cervical cancer	0.000206	0.00779	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—SERPIND1—cervical cancer	0.000206	0.00779	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—WNT2—cervical cancer	0.000205	0.00775	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—WNT2—cervical cancer	0.000203	0.00769	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Class A/1 (Rhodopsin-like receptors)—TAAR6—cervical cancer	0.0002	0.00758	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—WNT2—cervical cancer	0.000199	0.00753	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—TAAR6—cervical cancer	0.000194	0.00734	CbGpPWpGaD
Dihydroergotamine—ABCB1—Allograft Rejection—HLA-DPB1—cervical cancer	0.000191	0.00724	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—WNT2—cervical cancer	0.000187	0.00707	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—GP5—cervical cancer	0.00018	0.00681	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR ligand binding—WNT5A—cervical cancer	0.000155	0.00587	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR ligand binding—WNT5A—cervical cancer	0.000154	0.00583	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—TAAR6—cervical cancer	0.000153	0.00577	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—WNT2—cervical cancer	0.000152	0.00573	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—HES1—cervical cancer	0.000152	0.00573	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR ligand binding—WNT5A—cervical cancer	0.000151	0.0057	CbGpPWpGaD
Dihydroergotamine—ABCB1—Allograft Rejection—HLA-DQB1—cervical cancer	0.000149	0.00565	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—TAAR6—cervical cancer	0.000148	0.00561	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—TAAR6—cervical cancer	0.000147	0.00556	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—TAAR6—cervical cancer	0.000144	0.00545	CbGpPWpGaD
Dihydroergotamine—ABCB1—HIF-1-alpha transcription factor network—TERT—cervical cancer	0.000144	0.00543	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR ligand binding—WNT5A—cervical cancer	0.000142	0.00536	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—TAAR6—cervical cancer	0.000135	0.00512	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—TAAR6—cervical cancer	0.000135	0.00509	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—TAAR6—cervical cancer	0.000134	0.00505	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—TAAR6—cervical cancer	0.000131	0.00495	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—RARB—cervical cancer	0.000129	0.00488	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—TAAR6—cervical cancer	0.000123	0.00465	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—WNT2—cervical cancer	0.000119	0.00451	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR ligand binding—WNT5A—cervical cancer	0.000115	0.00435	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—TAAR6—cervical cancer	0.00011	0.00415	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—WNT2—cervical cancer	0.000105	0.00398	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—WNT2—cervical cancer	0.000104	0.00394	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—WNT2—cervical cancer	0.000102	0.00386	CbGpPWpGaD
Dihydroergotamine—HTR6—GPCR downstream signaling—AKAP13—cervical cancer	0.000102	0.00384	CbGpPWpGaD
Dihydroergotamine—HTR1D—GPCR downstream signaling—AKAP13—cervical cancer	0.000101	0.00381	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—TAAR6—cervical cancer	9.96e-05	0.00377	CbGpPWpGaD
Dihydroergotamine—HTR1B—GPCR downstream signaling—AKAP13—cervical cancer	9.87e-05	0.00373	CbGpPWpGaD
Dihydroergotamine—ABCB1—Allograft Rejection—CASP8—cervical cancer	9.76e-05	0.00369	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—WNT2—cervical cancer	9.59e-05	0.00363	CbGpPWpGaD
Dihydroergotamine—HTR2B—GPCR downstream signaling—AKAP13—cervical cancer	9.27e-05	0.00351	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—AKAP13—cervical cancer	9.23e-05	0.00349	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—AKAP13—cervical cancer	9.16e-05	0.00346	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR ligand binding—WNT5A—cervical cancer	9.03e-05	0.00342	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—AKAP13—cervical cancer	8.96e-05	0.00339	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—TAAR6—cervical cancer	8.62e-05	0.00326	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—AKAP13—cervical cancer	8.42e-05	0.00319	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—WNT5A—cervical cancer	7.96e-05	0.00301	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TAAR6—cervical cancer	7.95e-05	0.00301	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—WNT5A—cervical cancer	7.9e-05	0.00299	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TAAR6—cervical cancer	7.89e-05	0.00299	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—CASP3—cervical cancer	7.88e-05	0.00298	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—TAAR6—cervical cancer	7.83e-05	0.00296	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—WNT2—cervical cancer	7.78e-05	0.00294	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—WNT5A—cervical cancer	7.74e-05	0.00293	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TAAR6—cervical cancer	7.73e-05	0.00292	CbGpPWpGaD
Dihydroergotamine—HTR1A—SIDS Susceptibility Pathways—CTNNB1—cervical cancer	7.6e-05	0.00287	CbGpPWpGaD
Dihydroergotamine—HTR1A—GPCR downstream signaling—AKAP13—cervical cancer	7.52e-05	0.00284	CbGpPWpGaD
Dihydroergotamine—ABCB1—Allograft Rejection—CASP3—cervical cancer	7.38e-05	0.00279	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—WNT5A—cervical cancer	7.27e-05	0.00275	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TAAR6—cervical cancer	7.26e-05	0.00275	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—AKAP13—cervical cancer	6.83e-05	0.00258	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—WNT2—cervical cancer	6.21e-05	0.00235	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—WNT2—cervical cancer	6.16e-05	0.00233	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—WNT2—cervical cancer	6.11e-05	0.00231	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—WNT2—cervical cancer	6.03e-05	0.00228	CbGpPWpGaD
Dihydroergotamine—ADRA2A—GPCR downstream signaling—AKAP13—cervical cancer	5.91e-05	0.00224	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—WNT5A—cervical cancer	5.89e-05	0.00223	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TAAR6—cervical cancer	5.89e-05	0.00223	CbGpPWpGaD
Dihydroergotamine—HTR2B—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—cervical cancer	5.74e-05	0.00217	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—WNT2—cervical cancer	5.67e-05	0.00214	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—AKAP13—cervical cancer	5.45e-05	0.00206	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—AKAP13—cervical cancer	5.41e-05	0.00205	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—AKAP13—cervical cancer	5.37e-05	0.00203	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—AKAP13—cervical cancer	5.3e-05	0.002	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—AKAP13—cervical cancer	4.97e-05	0.00188	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP8—cervical cancer	4.82e-05	0.00182	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—WNT5A—cervical cancer	4.7e-05	0.00178	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—WNT5A—cervical cancer	4.67e-05	0.00177	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—WNT5A—cervical cancer	4.63e-05	0.00175	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TAAR6—cervical cancer	4.63e-05	0.00175	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—WNT2—cervical cancer	4.59e-05	0.00174	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—WNT5A—cervical cancer	4.57e-05	0.00173	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—WNT5A—cervical cancer	4.29e-05	0.00162	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—CA9—cervical cancer	4.08e-05	0.00154	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—AKAP13—cervical cancer	4.03e-05	0.00153	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—CASP3—cervical cancer	3.64e-05	0.00138	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—WNT2—cervical cancer	3.61e-05	0.00137	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—cervical cancer	3.51e-05	0.00133	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—WNT5A—cervical cancer	3.48e-05	0.00132	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOTCH2—cervical cancer	3.3e-05	0.00125	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOTCH2—cervical cancer	3.28e-05	0.00124	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOTCH2—cervical cancer	3.21e-05	0.00121	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—AKAP13—cervical cancer	3.17e-05	0.0012	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOTCH2—cervical cancer	3.01e-05	0.00114	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—CA9—cervical cancer	2.82e-05	0.00107	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—EGFR—cervical cancer	2.78e-05	0.00105	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—WNT5A—cervical cancer	2.74e-05	0.00104	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—HES1—cervical cancer	2.71e-05	0.00102	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—HES1—cervical cancer	2.69e-05	0.00102	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—HES1—cervical cancer	2.63e-05	0.000995	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—HES1—cervical cancer	2.47e-05	0.000935	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOTCH2—cervical cancer	2.44e-05	0.000925	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TERT—cervical cancer	2.37e-05	0.000897	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TERT—cervical cancer	2.35e-05	0.000891	CbGpPWpGaD
Dihydroergotamine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—cervical cancer	2.34e-05	0.000884	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TERT—cervical cancer	2.31e-05	0.000872	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—FGFR3—cervical cancer	2.18e-05	0.000823	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TERT—cervical cancer	2.17e-05	0.000819	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—FGFR3—cervical cancer	2.16e-05	0.000817	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—FGFR3—cervical cancer	2.12e-05	0.0008	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—NOTCH1—cervical cancer	2.04e-05	0.000773	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—NOTCH1—cervical cancer	2.03e-05	0.000767	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—HES1—cervical cancer	2e-05	0.000758	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—FGFR3—cervical cancer	1.99e-05	0.000752	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—NOTCH1—cervical cancer	1.99e-05	0.000751	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH2—cervical cancer	1.92e-05	0.000727	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—NOTCH1—cervical cancer	1.87e-05	0.000706	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling by GPCR—EGFR—cervical cancer	1.82e-05	0.000689	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling by GPCR—EGFR—cervical cancer	1.81e-05	0.000684	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling by GPCR—EGFR—cervical cancer	1.77e-05	0.000669	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TERT—cervical cancer	1.76e-05	0.000664	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—CA9—cervical cancer	1.74e-05	0.000657	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling by GPCR—EGFR—cervical cancer	1.66e-05	0.000629	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Metabolism—MTHFR—cervical cancer	1.66e-05	0.000626	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—FGFR3—cervical cancer	1.61e-05	0.00061	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—HES1—cervical cancer	1.57e-05	0.000596	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Hemostasis—TP53—cervical cancer	1.55e-05	0.000586	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—MTOR—cervical cancer	1.53e-05	0.000579	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—MTOR—cervical cancer	1.52e-05	0.000575	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—NOTCH1—cervical cancer	1.51e-05	0.000572	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—MTOR—cervical cancer	1.49e-05	0.000563	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CASP3—cervical cancer	1.41e-05	0.000533	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—MTOR—cervical cancer	1.4e-05	0.000529	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CASP3—cervical cancer	1.4e-05	0.000529	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TERT—cervical cancer	1.38e-05	0.000522	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CASP3—cervical cancer	1.37e-05	0.000518	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—CTNNB1—cervical cancer	1.36e-05	0.000514	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling by GPCR—EGFR—cervical cancer	1.35e-05	0.00051	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—CTNNB1—cervical cancer	1.35e-05	0.00051	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—CTNNB1—cervical cancer	1.32e-05	0.000499	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CASP3—cervical cancer	1.29e-05	0.000486	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—FGFR3—cervical cancer	1.27e-05	0.000479	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—CTNNB1—cervical cancer	1.24e-05	0.000469	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—NOTCH1—cervical cancer	1.19e-05	0.00045	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—STAT3—cervical cancer	1.18e-05	0.000448	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—STAT3—cervical cancer	1.17e-05	0.000444	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—STAT3—cervical cancer	1.15e-05	0.000435	CbGpPWpGaD
Dihydroergotamine—ABCB1—Metabolism—MTHFR—cervical cancer	1.14e-05	0.000433	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—MTOR—cervical cancer	1.13e-05	0.000429	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—STAT3—cervical cancer	1.08e-05	0.000409	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—EGFR—cervical cancer	1.08e-05	0.000407	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—EGFR—cervical cancer	1.07e-05	0.000404	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling by GPCR—EGFR—cervical cancer	1.06e-05	0.000401	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—EGFR—cervical cancer	1.05e-05	0.000395	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CASP3—cervical cancer	1.04e-05	0.000394	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—CTNNB1—cervical cancer	1.01e-05	0.00038	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—EGFR—cervical cancer	9.82e-06	0.000371	CbGpPWpGaD
Dihydroergotamine—HTR6—Signaling Pathways—TP53—cervical cancer	9.03e-06	0.000342	CbGpPWpGaD
Dihydroergotamine—HTR1D—Signaling Pathways—TP53—cervical cancer	8.96e-06	0.000339	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—MTOR—cervical cancer	8.91e-06	0.000337	CbGpPWpGaD
Dihydroergotamine—HTR1B—Signaling Pathways—TP53—cervical cancer	8.78e-06	0.000332	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—STAT3—cervical cancer	8.76e-06	0.000331	CbGpPWpGaD
Dihydroergotamine—HTR2B—Signaling Pathways—TP53—cervical cancer	8.24e-06	0.000312	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CASP3—cervical cancer	8.19e-06	0.00031	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—EGFR—cervical cancer	7.96e-06	0.000301	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—CTNNB1—cervical cancer	7.9e-06	0.000299	CbGpPWpGaD
Dihydroergotamine—CYP3A4—Metabolism—MTHFR—cervical cancer	7.05e-06	0.000267	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—STAT3—cervical cancer	6.89e-06	0.00026	CbGpPWpGaD
Dihydroergotamine—HTR1A—Signaling Pathways—TP53—cervical cancer	6.69e-06	0.000253	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—EGFR—cervical cancer	6.26e-06	0.000237	CbGpPWpGaD
Dihydroergotamine—ADRA2A—Signaling Pathways—TP53—cervical cancer	5.25e-06	0.000199	CbGpPWpGaD
